CRYOABLATION FOR
BREAST CANCER
Ultrasound-guided cryoablation destroys small breast tumours and symptomatic fibroadenomas without surgery — preserving breast tissue, avoiding general anaesthesia, and completing treatment in a single outpatient visit.
analyticsAt a Glance
- check_circleFDA-cleared for fibroadenoma ablation; evidence base growing for small invasive breast cancer ≤1.5 cm
- check_circleOutpatient procedure under local anaesthesia — no general anaesthesia, no surgical scar
- check_circleCryoablation combined with standard systemic therapy offers a breast-conservation alternative for selected patients
- check_circleAvailable at specialist breast interventional oncology centres in China and India via CancerFax
How Cryoablation Is Applied in Breast Oncology
Breast surgery — even lumpectomy — requires general anaesthesia, operating theatre time, and recovery leave. For patients with small invasive carcinomas or large symptomatic fibroadenomas, cryoablation offers a same-day, office-based alternative with comparable local outcomes in carefully selected cases.
“For a 1 cm hormone-receptor positive breast cancer in an elderly patient who declines surgery, cryoablation combined with endocrine therapy may provide durable disease control without a single incision.”
Small Invasive Breast Cancer
For unifocal invasive ductal carcinoma ≤1.5 cm, ER/PR-positive, HER2-negative, without EIC or LVI, cryoablation achieves complete pathological response in 75–88% of cases in prospective series — particularly in postmenopausal patients who are poor surgical candidates.
Breast Fibroadenoma
Cryoablation is FDA-cleared for the treatment of benign fibroadenomas ≤4 cm. The Visica 2 Treatment System has been evaluated in over 1,500 patients. Lesions reduce by 80–90% in volume within 12 months, with high patient satisfaction and no scarring.
Key Clinical Numbers
Published data from the ICE3 trial and fibroadenoma registries document the clinical outcomes of breast cryoablation.
- 75–88%Complete pathological response rate (small invasive BC)Reported in ICE3 and prospective series for unifocal ≤1.5 cm invasive carcinoma without EIC.
- >90%Patient satisfaction rate (fibroadenoma)Reported by Kaufman et al. in the largest prospective fibroadenoma cryoablation registry.
- 80–90%Fibroadenoma volume reduction at 12 monthsMost fibroadenomas treated with cryoablation are no longer palpable within 6–12 months.
- ≤1.5 cmOptimal invasive cancer lesion sizeLesions above this threshold have higher rates of incomplete ablation; multi-probe strategy needed for larger tumours.
How the Breast Cryoablation Procedure Is Performed
The procedure takes approximately 30–45 minutes and is performed in an outpatient clinic or procedure room under ultrasound guidance.
- 1
Ultrasound Lesion Mapping
Diagnostic ultrasound confirms the target lesion dimensions, depth, and orientation relative to the skin and chest wall.
- 2
Local Anaesthesia
Lidocaine is injected around the lesion and along the planned probe tract. Hydrodissection with saline may be used to displace the skin from the freezing zone.
- 3
Cryoprobe Insertion
A 2.4 mm or 1.47 mm cryoprobe is inserted through a small skin nick and positioned centrally within the target lesion under real-time ultrasound guidance.
- 4
Active Freeze Cycle
Argon gas cools the probe tip, and the ice-ball grows visibly on ultrasound until it encompasses the entire lesion with a 1 cm margin.
- 5
Passive Thaw and Second Freeze
The lesion thaws passively for 5 minutes, then a second freeze cycle is performed to ensure complete cell necrosis through the full ablation zone.
- 6
Probe Removal and Dressing
Probe is removed, gentle pressure applied, and a small dressing placed. No sutures required. Patients leave within 30 minutes of probe removal.
Benefits vs Limitations
Cryoablation is not a replacement for standard breast surgery in most patients — but it fills an important clinical gap for specific subgroups.
Benefits
- No general anaesthesia requiredPerformed under local anaesthesia — suitable for elderly patients, those with significant comorbidities, and anticoagulated patients who cannot safely undergo surgery.
- Breast anatomy preservedNo tissue is removed — the ablated lesion is resorbed in situ over months, preserving breast volume and avoiding contour deformity.
- No surgical scarOnly a 2–3 mm skin nick is needed for probe insertion — no excision scar, which is particularly valued in younger patients with fibroadenomas.
- Outpatient, same-day dischargeThe entire procedure and recovery takes 1–2 hours; patients return to normal activity within 24 hours in most cases.
Limitations
- No surgical specimen obtainedLocal ablation does not provide an excisional specimen for margin assessment — a core biopsy before the procedure must confirm histology and receptor status.
- Incomplete ablation riskLesions with extensive intraductal component (EIC) or lobular histology have significantly higher rates of incomplete response; these are relative contraindications.
- Nodal staging not addressedSentinel lymph node biopsy cannot be performed concurrently with percutaneous cryoablation; nodal staging must be addressed separately if indicated.
- Post-ablation imaging complexityTreated lesions take 6–12 months to fully resorb on imaging, requiring careful radiologist interpretation to distinguish post-ablation changes from recurrence.
Eligibility Criteria for Breast Cancer Cryoablation
The following criteria represent the consensus selection framework used in ICE3 and institutional protocols for invasive breast cancer cryoablation.
| Criterion | Required for Eligibility | Rationale |
|---|---|---|
| Tumour size | ≤1.5 cm (strict); ≤2 cm (selected) | Larger lesions have lower complete ablation rates with single-probe technique |
| Histology | Invasive ductal carcinoma (IDC) | ILC and tumours with EIC have higher incomplete ablation rates |
| EIC (extensive intraductal component) | Absent | EIC extends beyond core biopsy sampling — underestimates true tumour extent |
| Receptor status | ER+/PR+ preferred; HER2- preferred | Hormone-receptor positive tumours respond well to adjuvant endocrine therapy post-ablation |
| Lymphovascular invasion | Absent on biopsy | LVI predicts nodal involvement — sentinel node staging should precede ablation decision |
| Tumour visibility on ultrasound | Required | Procedure is entirely ultrasound-guided; CT or MRI-only lesions cannot be targeted with this technique |
More from the Cryoablation Therapy Resource Library
Continue exploring cryoablation — from the complete treatment overview to clinical applications across other tumour sites.
- Cryoablation Therapy — Complete Treatment Guide
- Cryoablation for Bone Metastases: Pain Control and Local Treatment
- Cryoablation for Liver Tumours: HCC and Metastases
- Cryoablation for Lung Cancer and Pulmonary Lesions
- Cryoimmunotherapy: Combining Cryoablation with Checkpoint Inhibitors
- Cryoablation for Kidney Cancer: Renal Cell Carcinoma
Frequently Asked Questions
Common questions from patients considering cryoablation for breast cancer or fibroadenoma.
Clinical Questions
Will the treated area feel lumpy or different after cryoablation?
Immediately after cryoablation, the treated area feels firm due to the ice-ball and initial oedema. Over 2–4 weeks this softens. A firm but gradually shrinking lump is typically palpable for 3–6 months as the ablated tissue resorbs. By 12 months, most patients report minimal residual change. The breast contour is preserved because no tissue is removed.
Does cryoablation replace the need for radiation therapy?
Not automatically. In standard breast cancer management, whole-breast or partial-breast radiation is recommended after lumpectomy to reduce local recurrence risk. The role of radiation after cryoablation in breast cancer is being defined in ongoing trials. Some protocols for small ER+ tumours in older patients combine cryoablation with endocrine therapy alone — omitting radiation — but this remains investigational outside of clinical trials for most patients.
Can cryoablation treat a fibroadenoma that is already large — say 3–4 cm?
Yes — cryoablation is FDA-cleared for fibroadenomas up to 4 cm. Larger fibroadenomas may require multi-probe placement to achieve complete coverage, but the procedure is technically feasible and effective. Reduction in palpability and volume is expected in the majority of patients within 6–12 months even for larger lesions.
I had a lumpectomy years ago. Can cryoablation treat a recurrence in the same breast?
Post-lumpectomy local recurrence is a complex situation. Cryoablation may be technically feasible for small, unifocal recurrences in a previously irradiated breast, but the decision requires careful multidisciplinary review. Prior radiation changes affect both eligibility assessment and interpretation of post-procedural imaging. CancerFax can facilitate a specialist oncology review of your case to assess whether this pathway is appropriate.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is Cryoablation Right for Your Breast Lesion?
CancerFax reviews your breast imaging, biopsy pathology, and oncology profile to determine whether cryoablation is appropriate for your specific tumour — and connects you with accredited breast ablation specialists in China or India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.